Most UK HealthTech founders do not sit down one day and decide to enter the US market. It is more of a slow accumulation. An inbound enquiry from a Boston health system. A competitor who just hired a VP of Sales in New York. An investor who keeps circling back to the same question in board meetings. A growing sense that the domestic market, however well you are doing in it, is starting to feel like a ceiling.
The question is rarely whether the US is the right destination. For ambitious UK HealthTech companies with proven products, it almost always is. The US healthcare market is worth $5.3 trillion and growing at 7.2% year on year. The digital health segment alone is projected to more than double over the next decade. There is no comparable opportunity anywhere else in the world for what you are building.
The real question is timing. Are you ready now? Or are you either talking yourself into it before the foundations are solid, or talking yourself out of it when they already are?
Here are ten honest signs that the time is now.
1. You have real product-market fit at home, and you can prove it.
Not “we think we have it.” Not “we are getting close.” Demonstrable, defensible fit. Customers who are renewing without being chased. Referrals coming in without incentives. A clear, crisp answer to the question of who buys your product, why they buy it, and what measurable difference it makes to their organisation.
This matters enormously for the US because the American healthcare market does not give you time to find your feet. US health systems, payers, and enterprise buyers are sophisticated, time-poor, and operating in a procurement environment with multiple competing vendors. If you cannot articulate your value proposition with precision, you will lose deals not because your product is inferior, but because someone else made it easier for the buyer to say yes. The companies that land quickly in the US are the ones who arrive already knowing exactly what they are selling and to whom. If you have that clarity at home, it travels.
☑ My customers renew without being chased
☑ I can explain who buys our product and why in two sentences
☑ We have clinical or commercial evidence we are proud to show
2. Inbound interest from the US is already finding you.
This is one of the most underrated signals, and one we see regularly with the UK HealthTech companies we work with. American health systems, digital health buyers, or US investors are reaching out without any targeted effort on your part. Someone found your website. A conference delegate passed on your details. A US-based NHS alum mentioned you to a contact in Boston.
If this is happening, the market is already telling you something important: the problem you solve exists in the US, people are looking for solutions, and you are visible enough to be found. That is not a small thing. Most UK companies entering the US have to manufacture their first conversations. You already have them. Do not let that signal go unanswered.
☑ We have had inbound enquiries from US companies or buyers
☑ American contacts have reached out at conferences or on LinkedIn
☑ We have US-based users or trial signups we did not actively target
3. Your domestic growth rate is starting to plateau.
This is the sign most founders are reluctant to admit out loud, but it is one of the most honest indicators of readiness. The UK digital health market, for all its energy, has a finite addressable customer base for any given product. When you start to feel that ceiling, when the pipeline conversations become more competitive, when the procurement cycles get longer, when the same names keep coming up, it is worth asking a hard question.
Is the energy and resource going into defending and incrementally growing UK market share generating the best possible return? For many companies at this stage, the answer is no. The same commercial effort pointed at the US, with its vastly larger buyer pool and higher contract values, would generate significantly more return. Plateauing at home is not a problem. It is often the clearest possible signal that you are ready to go bigger.
☑ Our UK pipeline feels increasingly competitive
☑ Growth has slowed compared to 12 to 18 months ago
☑ We are winning business but the effort-to-return ratio is increasing
4. A direct competitor has already made the move.
If a company you compete with directly has opened a US office, hired a US commercial lead, or started appearing at American HealthTech conferences, treat that as a competitive alarm. The US healthcare market rewards relationships. It rewards familiarity. A buyer who has heard of your competitor, who has had three conversations with their US sales lead, who has seen their case studies, is going to be significantly harder to win, even if your product is better.
First-mover advantage in the US is real. The company that builds trust and visibility with US health systems first gets shortlisted first, procured first, and referred on first. Watching a competitor build that while you plan is not caution. It is a strategic cost that compounds every quarter.
☑ A competitor has announced a US office or US hire in the last 12 months
☑ We are seeing US-based companies appear in our competitive landscape
☑ Competitors are presenting at US conferences we are not attending
5. Your investors are asking about the US in every board meeting.
If the US keeps coming up in board meetings and the question is shifting from “are you thinking about it?” to “when is it happening?”, that is not pressure to manage. It is a signal to act on. US traction changes your company’s valuation story in a fundamental way. A business that is operational in the US, even with one hire and two serious customer conversations, is a materially different proposition to one that has it on a slide in a deck.
If you are planning to raise your next round in the next 12 to 18 months and the US is on your roadmap, the time to start building that story is now, not when the round opens. Investors want to see momentum, not intention. You can read more about building US investor credibility here.
☑ The US comes up consistently in board or investor conversations
☑ Our next raise narrative depends partly on US progress
☑ Investors have asked specifically when we are entering the US
6. You have a person who could own the US expansion.
This is one of the most practical signs of readiness, and one of the most commonly overlooked. Entering the US without a named individual who owns the effort and has the authority to make decisions is one of the most reliable ways to waste 18 months and significant budget. It does not have to be a US hire on day one.
It can be an internal commercial leader who is prepared to spend meaningful time on the ground, build relationships, and make the market work.
What it cannot be is a collective responsibility spread across a leadership team that is already stretched. The US is too different, too complex, and too competitive for a committee approach.
The companies that gain traction quickly are almost always the ones where a single person is accountable, resourced, and excited about making it happen.
☑ We have a named person who would own the US effort
☑ That person has the commercial instincts to navigate an unfamiliar market
☑ Leadership is aligned and prepared to back them properly
7. Your product works for a US customer today, without a rebuild.
This sounds obvious but it is not always true, and being honest about it early saves significant time and money. Some UK HealthTech products require meaningful re-engineering to operate in the US: different compliance and data frameworks, different integration requirements with US EHR systems, different regulatory pathways.
None of these are insurmountable, but they take time, and they change your expansion timeline considerably.
If your product can be used by a US health system today without a significant rebuild, that is a genuine competitive advantage. It means you can move from first hire to first pilot faster than most.
If there is a rebuild required, scope that clearly before you start spending on US commercial activity, because the most expensive thing in market entry is generating customer interest in a product that is not yet ready to deliver.
☑ Our product can be deployed for a US customer today
☑ We understand the US compliance and data requirements relevant to us
☑ We have looked at US EHR integration requirements and have a view
8. You have at least 12 months of runway to do this properly.
The companies that struggle most with US expansion are not the ones with bad products or bad ideas. They are the ones who under-resourced the effort and pulled back at the first sign of difficulty, having spent enough to start but not enough to see results.
If you can commit a genuine 12-month runway to the US effort without putting your core business at risk, you are in a position to do this properly. You can get a realistic sense of what the investment looks like in our true cost of US expansion guide.
☑ We can fund US expansion for 12 months without affecting core operations
☑ We have modelled the costs and they are within what we can absorb
☑ Leadership is committed to seeing it through, not just starting it
9. You have already had real conversations with US buyers.
You do not need a signed contract to be ready. But if you have had genuine commercial conversations with US health systems, attended an American HealthTech conference, run a pilot with a US-based customer, or had a serious discussion with a US prospect who asked the right questions and pushed back on the right things, you are not starting from zero.
Those conversations are worth more than most founders realise. They tell you what US buyers care about, what language they use, what objections you need to address, and how your product lands in a different commercial context. The companies that move fastest in the US are the ones that arrive with some of this groundwork already done. If you have it, use it. It is a significant head start.
☑ We have had genuine commercial conversations with US health systems or buyers
☑ We have attended at least one US HealthTech event in the last 18 months
☑ We have a view on how our product lands with US buyers based on real feedback
10. You have been “nearly ready” for the US for over a year.
This is the most honest sign of all. If the US has been on your roadmap for 12 months or more, if the reasons for delay keep shifting but the conclusion stays the same, if you find yourself in the same conversation in board meetings that you were having a year ago, it is worth asking a direct question: what would actually have to be true for you to go?
No company crosses the Atlantic with every question answered. The ones that succeed are not the ones who waited for certainty. They are the ones who decided that the risk of not going was greater than the risk of going, and then built a structure around the move that made it manageable. The market is not getting less competitive while you plan.
Your competitors are not standing still. And the investment cycle the US is currently in will not last indefinitely.
☑ The US has been on our roadmap for over 12 months without meaningful progress
☑ The reasons for delay keep changing but the hesitation stays the same
☑ We know, honestly, that we are ready and are waiting for a confidence we will never fully have
So what does the first step look like?
Here is where most UK HealthTech companies are surprised by how accessible the US actually is. You do not need a US office. You do not need a full commercial team. You do not even need a US legal entity to hire your first person on the ground.
Through an Employer of Record service, you can hire a US-based employee compliantly, with local payroll, benefits, and tax obligations fully handled, without setting up a US entity at all. For many UK HealthTech companies, this is the right first move: get someone with market knowledge on the ground, start building relationships with US health systems, and learn what buyers actually respond to before you commit to a full infrastructure. When the commercial case is there, setting up a US entity is the natural next step.
One area that does catch UK companies off-guard is the cultural dimension. The commercial language is different, the management expectations are different, and the way you build trust with buyers and employees requires adjustment. Our guide to mastering US business culture is a useful starting point, and our comprehensive UK to US expansion guide covers the full landscape of what to expect.
At Foothold America, we have helped hundreds of UK and European companies work through exactly this transition. We handle entity setup, Employer of Record hiring, payroll, HR compliance, bookkeeping, and talent acquisition, so your leadership team stays focused on the commercial opportunity rather than the operational complexity of entering a new market. We know what works, we know what trips companies up, and we have done this enough times to move quickly when the timing is right.
If you are ticking boxes on this list, the best next step is a conversation. Visit footholdamerica.com or get in touch with our UK team directly.
Foothold America is a Boston-based US expansion specialist helping international businesses, primarily from the UK and Europe, hire, operate and grow in the United States. Services include US entity setup, Employer of Record, PEO+ Cross-Border Support, talent acquisition, and Cultural Intelligence Advisory.
